The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Safe Step Act of 2021 Aims to Put Patients First

Safe Step Act of 2021 Aims to Put Patients First

March 5, 2021 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On Feb. 25, Sen. Lisa Murkowski (R-Alaska), Sen. Maggie Hassan (D-N.H.), Sen. Bill Cassidy (R-La.) and Sen. Jacky Rosen (D-Nev.) introduced the Safe Step Act of 2021 (S. 464) to improve step therapy protocols and ensure continued patient access to treatments proven to be the most safe and efficient treatment for them.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
  • Texas Rheumatologists Push for Passage of Step Therapy Reforms
  • Trump Aims at Insurers in Battle Over Healthcare Subsidies
Explore This Issue
April 2021
Also By This Author
  • Changes & Additions to RISE Measures in 2020

Step therapy—also known as fail first—is a troubling practice employed by most insurers that forces patients to try therapies preferred by the insurance company before the therapy their doctor prescribed will be approved, even when providers are certain the initial therapies will not be effective. Step therapy ranks the financial benefit of insurers and pharmacy benefit managers above the judgment of healthcare providers and poses unnecessary risk to patients’ health by delaying effective treatment. Step therapy is tantamount to practicing medicine without a license; we advocate that providers be empowered to treat their patients appropriately and in accordance with accepted guidelines. Although many states have acted on this issue, federal legislation is necessary to address this threat to the health of patients covered by group health plans nationwide.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Safe Step Act of 2021 would amend the Employee Retirement Income Security Act (ERISA) to require group health plans provide a process for medical exceptions for any step therapy protocol by:

  • Establishing a clear exemption process: The Safe Step Act requires insurers implement a clear and transparent process for a patient or provider to request an exception to a step therapy protocol;
  • Requiring group health plans respond to an exemption request within 72 hours in all circumstances—and 24 hours if the patient’s life is at risk; and
  • Codifying five circumstances in which group health plans are required to grant an exception to step therapy protocols. If:
  1. The patient has already tried the preferred drug and it failed as an effective treatment;
  2. The preferred drug is reasonably expected to be ineffective and a delay of effective treatment would yield severe or irreversible consequences;
  3. The preferred treatment is contraindicated or has caused/is likely to cause an adverse reaction;
  4. The preferred drug will prevent the patient from fulfilling their occupational responsibilities at work or performing basic activities, such as eating, using the toilet, grooming, dressing and bathing; or
  5. The patient is already stable on a treatment regimen selected by their provider and that drug was covered by their previous insurance plan.

Step therapy protocols often ignore a patient’s individual needs and unique medical history. That means patients may have to retry medications that previously failed to effectively treat their disease or that could have dangerous side effects. Treatments for rheumatic conditions are not one-size-fits-all and must be carefully tailored to a patient’s individual needs. Many patients must try multiple drugs before finding one that works best for them. Step therapy unnecessarily draws out this process by requiring patients to try and fail to respond to drugs their doctors know will not be effective, resulting in de facto denial of care.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: American College of Rheumatology, Legislation & Advocacy Tagged With: Legislation, Safe Step Act, step therapyIssue: April 2021

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
  • Texas Rheumatologists Push for Passage of Step Therapy Reforms
  • Trump Aims at Insurers in Battle Over Healthcare Subsidies
  • The ACR and Partners Help Get Legislation Passed in New York to Limit Step Therapy

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.